There has long been an interest in examining the involvement of opioid neurotransmission in nicotine rewarding process and addiction to nicotine. Over the past 3 decades, however, clinical effort to test the effectiveness of nonselective opioid antagonists (mainly naloxone and naltrexone) for smoking cessation has yielded equivocal results. In light of the fact that there are three distinctive types of receptors mediating actions of the endogenous opioid peptides, this study, using a rat model of nicotine self-administration, examined involvement of different opioid receptors in the reinforcement of nicotine by selective blockade of the μ1, the δ, and the κ opioid receptors. Male Sprague-Dawley rats were trained in daily 1 h sessions to intravenously self-administer nicotine (0.03 mg/kg/infusion) on a fixed-ratio 5 schedule. After establishment of stable nicotine self-administration behavior, the effects of the opioid antagonists were tested. Separate groups of rats were used to test the effects of naloxanazine (selective for μ1 receptors, 0, 5 and 15 mg/kg), naltrindole (selective for δ receptors, 0, 0.5 and 5 mg/kg), and 5′-guanidinonaltrindole (GNTI, selective for κ receptors, 0, 0.25 and 1 mg/kg). In each individual drug group, the 3 drug doses were tested by using a withinsubject and Latin-Square design. The effects of these antagonists on food self-administering behavior were also examined in the same rats in each respective drug group after retrained for food self-administration. Pretreatment with naloxonazine, but not naltrindole or GNTI, significantly reduced responses on the active lever and correspondingly the number of nicotine infusions. None of these antagonists changed lever-pressing behavior for food reinforcement. These results indicate that activation of the opioid μ1, but not the δ or the κ, receptors is required for the reinforcement of nicotine and suggest that opioid neurotransmission via the μ1 receptors would be a promising target for the development of opioid ligands for smoking cessation.
Introduction
Tobacco smoking is one of the leading preventable causes of death in the United States (USDHHS, 2004) . The adverse health effects from smoking account for an estimated 438,000 deaths, or nearly 1 of every 5 deaths, each year (CDC, 2004 (CDC, , 2005 . Moreover, the prevalence of smoking still remains high with an approximate 22% of adults and 24% of youth being currently smokers (CDC, 2004) . Although there have been several pharmacological treatments available, i.e. nicotine replacement therapy, bupropion, and varenicline, long-term abstinence rates even on these drug treatment are unsatisfactorily low. The 1-year abstinence rates are ≤16.1% for bupropion, ≤ 20.3% for nicotine replacement and ≤26.1% for varenicline (Aubin et al., 2008; Gonzales et al., 2006; Jorenby et al., 2006) . Therefore, there is an imperative need to develop more effective treatments for tobacco smoking.
Increasing evidence has shown that opioid neurotransmission is implicated in mediating rewarding actions and dependence of drugs of abuse including nicotine (Berrendero et al., 2010; Gianoulakis, 2004; Le Merrer et al., 2009; Pomerleau, 1998; Xue and Domino, 2008) . For instance, nicotine administration has been found to increase expression and release of opioid peptides in mesolimbic regions (Boyadjieva and Sarkar, 1997; Davenport et al., 1990; Dhatt et al., 1995; Houdi et al., 1998; Houdi et al., 1991; Pierzchala et al., 1987) . Opioid receptor antagonists have been reported to decrease nicotine-induced dopamine release in the nucleus accumbens, an important terminal region of the mesolimbic dopamine circuitry (Tanda and Di Chiara, 1998), reduce nicotine reward (Walters et al., 2005; Zarrindast et al., 2003) , and precipitate withdrawal symptoms in rats treated chronically with nicotine (Malin et al., 1993) . Over the past 3 decades, however, clinical effort to test the effectiveness of opioid antagonists (mainly naloxone and naltrexone) for smoking cessation has yielded equivocal results: some trials reported that these antagonists reduced consumption of cigarettes while others failed to find any benefit (e.g., Gorelick et al., 1988; Karras and Kane, 1980; King et al., 2006; King and Meyer, 2000; Krishnan-Sarin et al., 1999; Nemeth-Coslett and Griffiths, 1986; Ray et al., 2006; Rukstalis 
